StockData
Viridian Therapeutics, Inc.\DE logo

Viridian Therapeutics, Inc.\DE (VRDN) stock

VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)

Close on Nov 18, 2026Market cap $3.41BP/E –Yield –

Viridian Therapeutics, Inc.\DE profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Viridian Therapeutics, Inc.\DE's profit margin for the twelve months ending Jun 30, 2026 was -544.1%. For fiscal 2025 it was -483.6%, against -89387.1% the year before. The highest annual figure on record is -39.3% in fiscal 2013.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-483.6%+88903.5
FY2024Dec 31, 2024-89387.1%−13675.6
FY2023Dec 31, 2023-75711.5%−68382.2
FY2022Dec 31, 2022-7329.2%−4649.1
FY2021Dec 31, 2021-2680.2%+7864.1
FY2020Dec 31, 2020-10544.3%−9605.6
FY2019Dec 31, 2019-938.6%−548.7
FY2018Dec 31, 2018-390.0%+272.3
FY2017Dec 31, 2017-662.3%−165.5
FY2016Dec 31, 2016-496.8%−50.5
FY2015Dec 31, 2015-446.3%−324.7
FY2014Dec 31, 2014-121.7%−82.3
FY2013Dec 31, 2013-39.3%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-44760.2%+89553.1
Q1 FY2026Mar 31, 2026-74397.9%+46313.2
Q4 FY2025Dec 31, 2025-91178.0%+19551.1
Q3 FY2025Sep 30, 2025-49.0%+89124.2
Q2 FY2025Jun 30, 2025-134313.3%−44045.3
Q1 FY2025Mar 31, 2025-120711.1%−53291.7
Q4 FY2024Dec 31, 2024-110729.2%−17868.1
Q3 FY2024Sep 30, 2024-89173.3%−22978.8
Q2 FY2024Jun 30, 2024-90268.1%−13791.7
Q1 FY2024Mar 31, 2024-67419.4%+2122.4
Q4 FY2023Dec 31, 2023-92861.1%−49256.3
Q3 FY2023Sep 30, 2023-66194.4%−63775.6
Q2 FY2023Jun 30, 2023-76476.4%−64956.5
Q1 FY2023Mar 31, 2023-69541.8%−57646.9
Q4 FY2022Dec 31, 2022-43604.8%−30078.6
Q3 FY2022Sep 30, 2022-2418.8%+4332.6
Q2 FY2022Jun 30, 2022-11519.9%−9871.8
Q1 FY2022Mar 31, 2022-11894.9%−10622.7
Q4 FY2021Dec 31, 2021-13526.2%+154514.6
Q3 FY2021Sep 30, 2021-6751.4%−2921.1
Q2 FY2021Jun 30, 2021-1648.1%−676.6
Q1 FY2021Mar 31, 2021-1272.2%−122.5
Q4 FY2020Dec 31, 2020-168040.7%−166424.9
Q2 FY2020Jun 30, 2020-3830.4%−3476.5
Q1 FY2020Mar 31, 2020-971.5%+2154.6
Q4 FY2019Dec 31, 2019-1149.8%+1017.7
Q3 FY2019Sep 30, 2019-1615.8%−661.3
Q2 FY2019Jun 30, 2019-353.9%+45.5
Q1 FY2019Mar 31, 2019-3126.1%−3028.6
Q4 FY2018Dec 31, 2018-2167.4%−1631.7
Q3 FY2018Sep 30, 2018-954.6%−596.9
Q2 FY2018Jun 30, 2018-399.4%+619.0
Q1 FY2018Mar 31, 2018-97.4%+1413.4
Q4 FY2017Dec 31, 2017-535.7%+637.9
Q3 FY2017Sep 30, 2017-357.7%+86.0
Q2 FY2017Jun 30, 2017-1018.4%–
Q1 FY2017Mar 31, 2017-1510.8%–
Q4 FY2016Dec 31, 2016-1173.7%–
Q3 FY2016Sep 30, 2016-443.7%–

More Viridian Therapeutics, Inc.\DE figures

See a number that looks wrong?